

## WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:
A61K 31/00
A2
(11) International Publication Number: WO 98/02151
(43) International Publication Date: 22 January 1998 (22.01.98)

(21) International Application Number:

PCT/US97/12120

(22) International Filing Date:

11 July 1997 (11.07.97)

(30) Priority Data:

60/021,716

12 July 1996 (12.07.96)

US

(71) Applicant: LEUKOSITE, INC. [US/US]; 215 First Street, Cambridge, MA 02142 (US).

(72) Inventors: SCHWENDER, Charles, F.; 577 East Hill Road, Glen Gardner, NJ 08826 (US). MACKAY, Charles, R.; 126 Church Street, Watertown, MA 02172 (US). PINTO, Julia, C.; 8 Chubb's Brook Lane, Beverly Farms, MA 01915 (US). NEWMAN, Walter, 8 Durham Street No. 3, Boston, MA 02115 (US).

(74) Agents: BROOK, David, E. et al.; Hamilton, Brook, Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA 02173 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

## Published

Without international search report and to be republished upon receipt of that report.

(54) Title: CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR

## (57) Abstract

Disclosed is a method of treating a subject with a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to the subject a therapeutically effective amount of a compound represented by structural formula (I) and

$$Z$$
— $Y$ — $(CH2) $\overline{n}$ — $X$ — $N$ 
 $R_b$ 
(I)$ 

physiologically acceptable salts thereof. Z is a substituted or unsubstituted aromatic group. Y is a covalent bond, -O- or -CO-. n is an integer from one to about five. X is a covalent bond or -CO-.  $R_a$  is an aliphatic or a substituted aliphatic group;  $R_b$  is an aliphatic group substituted with an aromatic group or substituted aromatic group; and, taken together with the nitrogen atom bonded to  $R_a$  and  $R_b$ , can form a substituted or unsubstituted non-aromatic heterocyclic ring.